Webflow Homepage
Our Science
Veterinarians
For Canine lymphoma & Leukemia
Personalized Prediction Profile
AI-Driven Drug Response Predictions
(Flow Cytometry + PARR included)
Immunoprofile
Get definitive diagnostic support from the start
(Flow Cytometry + PARR)
Flow Cytometry
Accurately determine lymphoma or leukemia subtypes
PARR
Determine the diversity of B-cell and T-cell clones
For Canine Patients
Multidrug Sensitivity Genotyping (MDR1)
Identify MDR1 carrier status with ease
for veterinarians
Order Services via Vet Portal
Request Sample Reports
See what you will get when you order ImpriMed's services
Become an ImpriMed Provider
Participate in Our Research
Veterinary Cancer Pioneers Podcast
Contact Us
Pet Parents
LEARN
How It Works
Lymphoma 101
Blog
Content Library
Get Started
Find a Veterinary Oncologist
Talk to Your Veterinarian
Customer stories & Case Studies
ImpriMed Reviews
Discover what other pet parents are saying and how oncologists use ImpriMed's reports
Company
Company
About Us
Careers
Press
Contact Us
Contact Us
Other Links
ImpriMed Korea
Pricing
Find a Vet
Get Started
Press
ImpriMed
in the news
For press opportunities, please email
press@imprimedicine.com.
Latest Stories
Button Text
In the News
Button Text
Presentations
Button Text
Press Releases
Button Text
Scientific Publications
Button Text
Video/Podcast Interviews
Press Releases
ImpriMed Celebrates the Milestone of 4,000 Dog Blood Cancer Patients
Business Insider
Learn More →
Press Releases
ImpriMed Wins Place at the Mayo Clinic Platform_Accelerate Immersive Program
EIN Presswire
Learn More →
Press Releases
40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder
EIN Presswire
Learn More →
Press Releases
ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference
EIN Presswire
Learn More →
Press Releases
ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes
EIN Presswire
Learn More →
Press Releases
ImpriMed Publishes Exclusive Canine Patients Data Analysis
EIN Presswire
Learn More →
Press Releases
ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice
EIN Presswire
Learn More →
Press Releases
ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion
EIN Presswire
Learn More →
Press Releases
ImpriMed Launches New Diagnostic Services for Canine Lymphoma
EIN Presswire
Learn More →
Press Releases
ImpriMed Initiates Feline Lymphoma Drug Response Prediction Study
EIN Presswire
Learn More →
Press Releases
ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma
GlobeNewswire
Learn More →
Press Releases
ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market
GlobeNewswire
Learn More →
Press Releases
ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers
PR Underground
Learn More →
Press Releases
ImpriMed Raises $4M for Customized Cancer Treatments for Dogs
GlobeNewswire
Learn More →
